Welcome to our dedicated page for Allarity Therapeutics SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allarity Therapeutics, Inc. SEC filings document the company’s clinical-stage oncology business, capital structure, governance, and material-event disclosures. The filings identify Allarity’s Nasdaq-listed common stock and emerging growth company status, and include 8-K reports covering Regulation FD presentations, scientific and clinical updates for stenoparib and the DRP® companion diagnostic, intellectual-property developments, operating and financial results, and promissory-note financing.
Proxy materials describe annual meeting matters and stockholder voting procedures, while material definitive agreement filings and other current reports provide formal disclosure on financing arrangements, corporate progress, and regulatory or clinical communications tied to Allarity’s precision oncology programs.
Allarity Therapeutics, Inc. furnished an investor presentation and announced a speaking engagement by its CEO under a current report. The materials focus on stenoparib, an oral dual inhibitor of PARP and the WNT/tankyrase pathway, and the company’s Drug Response Predictor (DRP®) companion diagnostic platform.
The presentation highlights Phase 2 monotherapy data in heavily pretreated, platinum-resistant ovarian cancer, where stenoparib given twice daily showed a reported median overall survival of 22 months and extended benefit in patients with higher stenoparib-DRP scores. Allarity also describes ongoing Phase 2 trials in ovarian cancer and relapsed small cell lung cancer, and notes that its CEO will present “Dual Inhibition of PARP and WNT” at Precision Medicine Forum Europe 2026 in Stockholm.
McLaughlin Gerald W. reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics, Inc. director Gerald W. McLaughlin received a grant of 45,000 shares of common stock in the form of restricted stock units on January 28, 2026. These RSUs vested in full on the grant date, bringing his directly held position to 70,000 shares after the award.
Allarity Therapeutics, Inc. reports that its active pharmaceutical ingredient manufacturing campaign for stenoparib is progressing as planned, with completion expected no later than the third quarter of 2026 at a GMP-compliant contract manufacturer in Europe. This Phase 3-focused campaign is intended to secure drug supply to support a potential pivotal trial in advanced ovarian cancer following FDA Fast Track designation.
The company states that all manufacturing-related payments have been completed and that no additional cash outlays for this manufacturing campaign are anticipated. Ongoing Phase 2 trials in advanced ovarian cancer and relapsed small cell lung cancer continue to enroll patients, supported by Allarity’s DRP companion diagnostic approach.
Allarity Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 26, 2026. Proposals include electing one Class I director, ratifying Wolf & Company as auditor for 2026, and an advisory say-on-pay vote on named executive officer compensation.
The company seeks approval to raise its 2021 Equity Incentive Plan share pool from 1,521,990 to 2,021,990 shares and to permit potential issuance of more than 19.99% of outstanding common stock under a $6,000,000 equity line with Tumim Stone Capital, subject to Nasdaq rules and ownership caps. Stockholders are also asked to approve an amendment adding Delaware-permitted officer exculpation and to authorize potential adjournment of the meeting to solicit additional proxies if needed.
Graff Jeremy R. reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics, Inc. reported that officer Jeremy R. Graff received a grant of 133,333 shares of common stock in the form of restricted stock units on January 28, 2026. The award was granted at a stated price of $0.00 per share as equity compensation.
The RSUs were issued under Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan and will vest in three equal installments on the first, second, and third anniversaries of the grant date, as long as Graff maintains a continued relationship with the company. Following this grant, he directly holds 381,644 shares of common stock.
Ervin Jeffrey S reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics, Inc. reported that its CFO, Jeffrey S. Ervin, received a grant of 150,000 shares of Common Stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he holds 150,000 shares directly.
The RSUs were granted on January 28, 2026 under Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan. They will vest in equal one-third installments on the first, second, and third anniversaries of the grant date, if he continues his relationship with the company through each vesting date.
Allarity Therapeutics, Inc. reported that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its patent application covering the DRP® companion diagnostic specific to its cancer drug candidate stenoparib. The patent is expected to be formally granted within three months, subject to standard administrative procedures, and would provide exclusivity at least into 2039 for stenoparib when used together with the DRP® test.
The allowed claims cover methods for predicting clinical benefit from stenoparib using gene expression profiles and selecting patients most likely to respond. Allarity already holds European and Australian patents for the Stenoparib DRP® and 18 granted patents for other drug-specific DRPs, including eight in the United States. The company continues Phase 2 development of stenoparib in ovarian cancer and small cell lung cancer while pursuing additional DRP® patent protection globally.
Allarity Therapeutics is registering the resale of up to 255,103 shares of its common stock. This prospectus covers resale of those shares by a selling stockholder (the shares were issued in a private placement on December 23, 2025). The Company will receive no proceeds from these resales.
The prospectus states the selling stockholder may sell the Shares from time to time on Nasdaq or in private transactions at prevailing market or negotiated prices. The prospectus also discloses prior related financings, including a September 23, 2025 private placement generating approximately $2.5 million in gross proceeds and an Additional Closing on December 23, 2025 that issued 255,103 shares at $0.98 per share.